Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002907 · ClinicalTrials.gov registry record · Phase 2
Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
A Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Study location
NCT00002907 is a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm that has completed, run by Barbara Ann Karmanos Cancer Institute. The trial reports 1 study location across 1 state.
The verdict
NCT00002907, a Phase 2 study of Multiple Myeloma and Plasma Cell Neoplasm, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with relapsed multiple myeloma.
Conditions Studied
Interventions
- DRUG bryostatin 1
Study Locations (1)
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-01 |
| Est. Completion | 2000-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002907
The ClinicalTrials.gov registry entry for NCT00002907 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma and Plasma Cell Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which bryostatin 1 is the first listed.
NCT00002907 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00002907 about?
NCT00002907 is a clinical study titled "Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients with relapsed multiple myeloma.
What is the current status of trial NCT00002907?
This trial is currently completed. It is a Phase 2 study. The study started on 1997-01. Estimated completion is 2000-11.
What conditions does trial NCT00002907 study?
This clinical trial studies the following conditions: Multiple Myeloma and Plasma Cell Neoplasm.
What interventions are being tested in trial NCT00002907?
The interventions under investigation include: bryostatin 1 (DRUG).
Who is sponsoring clinical trial NCT00002907?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002907 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma and Plasma Cell Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
COMPLETED · Phase 2
-
O6-benzylguanine And Carmustine in Treating Patients With Multiple Myeloma
COMPLETED · Phase 2
-
Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
COMPLETED · Phase 2
-
Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma
COMPLETED · Phase 2
-
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
COMPLETED · Phase 2
-
Campath-1H + FK506 and Methylprednisolone for GVHD
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.